Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOSA-2: Antihypertensives in OSA
NCT02896621Phase 3Completed
- Sponsor
- Hospital de Clínicas de Porto Alegre
- Start
- Dec 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of chlorthalidone and amiloride in hypertension (HTN) (2 arms), sponsored by Hospital de Clínicas de Porto Alegre. Primary endpoint: Ratio of early to late diastolic filling velocities at 8 weeks. Started Dec 2014; status: completed.
02
Drugs
chlorthalidoneamiloride
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02896621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02896621.